These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2943589

  • 1. In vitro studies of S-25930 and S-25932, two new 4-quinolones.
    Piddock LJ, Andrews JM, Diver JM, Wise R.
    Eur J Clin Microbiol; 1986 Jun; 5(3):303-10. PubMed ID: 2943589
    [Abstract] [Full Text] [Related]

  • 2. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [Abstract] [Full Text] [Related]

  • 3. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA, Noone P.
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [Abstract] [Full Text] [Related]

  • 4. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of the newer quinolones compared with the classic ones and tobramycin.
    Boquet Jiménez E, Dalet Escribá F, Caballé L.
    Infection; 1985 Apr; 13(4):193-6. PubMed ID: 2931382
    [Abstract] [Full Text] [Related]

  • 6. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 7. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL, van der Ros-van de Repe J, van Veldhuizen G.
    Antimicrob Agents Chemother; 1983 Aug; 24(2):302-4. PubMed ID: 6227281
    [Abstract] [Full Text] [Related]

  • 8. In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin.
    Husson MO, Izard D, Leclerc H.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Dec; 258(2-3):283-6. PubMed ID: 6241772
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.
    Piddock LJ, Diver JM, Wise R.
    Eur J Clin Microbiol; 1986 Aug; 5(4):411-5. PubMed ID: 3758052
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
    Smith BR, LeFrock JL, Donato JB, Joseph WS, Weber SJ.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):355-8. PubMed ID: 3717937
    [Abstract] [Full Text] [Related]

  • 12. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL, Jones RN.
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A.
    Scand J Infect Dis; 1985 Jun; 17(1):91-4. PubMed ID: 3158070
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A, Petermüller C.
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM, Zemcov SJ.
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [Abstract] [Full Text] [Related]

  • 16. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE, Wickerhoff-Minoggio T.
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [Abstract] [Full Text] [Related]

  • 17. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R, Esteve M, Moros M, Xicota MA, Parés J.
    Drugs Exp Clin Res; 1987 Oct; 13(2):75-7. PubMed ID: 3582134
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Hoogkamp-Korstanje JA.
    Eur J Clin Microbiol; 1984 Aug; 3(4):333-8. PubMed ID: 6237901
    [Abstract] [Full Text] [Related]

  • 19. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L, Saunders J, Traynor R, Koornhof HJ.
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents.
    Neu HC, Chin NX.
    J Antimicrob Chemother; 1987 Feb; 19(2):175-85. PubMed ID: 3571042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.